Bristol-Myers Squibb Company
Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The compan…
Drug Manufacturers - General
US, New York [HQ]
FA
Fundamental Analysis · Most Recent Quarter
A dedicated fundamental analysis might help you to get a quick overview
of the
financial stability. It is important to understand the
FA Algorithm
and the criterias before valuing it as a top-tier resource.
Fundamentals
Valuation
| Metric | Q4 | Q1 | Δ in % | |
|---|---|---|---|---|
| EV/EBITDA | 8.08 | 34.92 | 32.31 | |
| Graham Fair Price | 95.00 | 32.86 | 16.85 | |
| PEG | -99.85 | < 0.005 | -1.98 | |
| Price/Book | 83.95 | 6.50 | 3.53 | |
| Price/Cash Flow | 58.53 | 42.04 | 26.52 | |
| Prices/Earnings | -84.75 | -2.25 | 14.76 | |
| Price/Sales | -0.30 | 9.03 | 9.06 | |
| Price/FCF | 58.53 | 42.04 | 26.52 | |
| Naive Interpretation | member | |||
01 - Valuation ·
Weak
Fundamentals
Profitability
| Metric | Q4 | Q1 | Δ in % | |
|---|---|---|---|---|
| Gross Profit Margin | -1.04 | 0.75 | 0.76 | |
| Operating Margin | 122.35 | 0.33 | 0.15 | |
| ROA | 549.56 | -0.12 | 0.02 | |
| ROE | 0.06 | -0.72 | 1106.46 | |
| ROIC | 0.03 | 0.05 | 116.64 | |
| Naive Interpretation | member | |||
02 - Profitability ·
Not Interpreted
Fundamentals
Financial Growth
| Metric | Q4 | Q1 | Δ in % | |
|---|---|---|---|---|
| Debt QOQ | 0.38 | 0.06 | 587.31 | |
| Dividends QOQ | -0.01 | 0.05 | 303.78 | |
| EBIT QOQ | -0.60 | 1.30 | 116.28 | |
| EPS QOQ | -0.07 | -7.77 | -10334.15 | |
| FCF QOQ | -0.11 | -0.35 | -216.71 | |
| Revenue QOQ | 0.05 | 0.03 | -27.45 | |
| Naive Interpretation | member | |||
03 - Financial Growth ·
Weak
Fundamentals
Leverage & Liquidity
| Metric | Q4 | Q1 | Δ in % | |
|---|---|---|---|---|
| Assets Turnover | n.A. | n.A. | n.A. | |
| Days Inventory Outstanding (DIO) | 87.28 | 91.63 | 4.98 | |
| Days Sales Outstanding (DSO) | 119.70 | 106.65 | -10.90 | |
| Inventory Turnover | 1.03 | 0.98 | -4.75 | |
| Debt/Capitalization | 0.58 | 0.78 | 32.82 | |
| Quick Ratio | 1.24 | 0.92 | -25.72 | |
| Naive Interpretation | member | |||
04 - Leverage & Liquidity ·
Bad
Fundamentals
Per Share Metrics
| Metric | Q4 | Q1 | Δ in % | |
|---|---|---|---|---|
| Book Value | 14.52 | 8.15 | -43.86 | |
| Cash | 6.06 | 4.78 | -21.10 | |
| Capex | -0.16 | -0.14 | 13.77 | |
| Free Cash Flow | 1.93 | 1.26 | -34.85 | |
| Revenue | 5.66 | 5.87 | 3.59 | |
| Naive Interpretation | member | |||
05 - Per Share Metrics ·
Weak
Fundamentals
Financial Health
06 - Financial Health ·
Bad